UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases
UCB (EBR: UCB) announced on May 3, 2026, a definitive agreement to acquire Candid Therapeutics...
Deals
SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease
SiranBio, a Suzhou-based siRNA drug developer, announced a strategic licensing agreement with GlaxoSmithKline plc (GSK;...
Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Emalex Biosciences announced a definitive acquisition agreement under...
Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline
Eccogene Inc., a Sino-U.S. biotechnology company founded in 2018, has filed its prospectus for an...
Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has assumed exclusive licensing rights from...
Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets
Fosun Pharma (SHA: 600196; HKG: 2196) announced it has signed a Memorandum of Cooperation with...
Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced a strategic partnership with Sun...
Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801
Vivacta Biotechnology, a Shanghai-based in vivo chimeric antigen receptor (CAR)-T therapy developer, announced the successful...
Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
Thermo Fisher Scientific Inc. (NYSE: TMO) announced on April 27, 2026, that it has signed...
Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design
Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of its Series...
Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
Adcoris, a Hangzhou-based bioconjugation specialist, announced a global licensing agreement with U.S.-headquartered K2 Therapeutics, Inc....
Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
Chia Tai Tianqing Pharmaceutical Group, a wholly owned subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177),...
Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets
Beijing QL Biopharmaceutical Co., Ltd., a clinical-stage biotech founded in 2018, has filed a prospectus...
China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio
Boya Biological Pharmacy Co., Ltd., (SHE: 300294) a China-based pharmaceutical company, has agreed to divest...
Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology
Johnson & Johnson (J&J, NYSE: JNJ) announced on 24 April 2026 a definitive agreement to...
Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
Star Sports Medicine Co., Ltd., a Chinese sports medical device manufacturer, successfully completed its initial...
Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market
Sisram Medical Ltd (HKG: 1696), an Israel-based aesthetic medical technology company and subsidiary of Fosun...
SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model
SciClone Pharmaceuticals Inc (HKG: 6600) announced a strategic partnership agreement with JD Healthcare (HKG: 6618),...
Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses
Sipai Health Technology Co., Ltd. (HKG: 0314), also known as Mebanks, has announced the sale...
AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio
AbbVie (NYSE: ABBV) has announced plans to invest $1.4 billion to construct a state-of-the-art pharmaceutical...